Form 4: Alto Neuroscience's Chief Medical Officer Increases Stake in Company

Adam Savitz, Chief Medical Officer of Alto Neuroscience, recently increased his indirect holdings in the company's common stock through purchases made via a trust.

Summary

• On July 9th and 10th, 2024, Adam Savitz, the Chief Medical Officer of Alto Neuroscience, indirectly acquired shares of common stock through purchases made by the Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz.
• On July 9, 2024, 10,681 shares were purchased at a weighted average price of $12.53, with individual prices ranging from $12.05 to $13.04.
• An additional 1,388 shares were purchased on July 9, 2024, at $13.15 per share.
• On July 10, 2024, 2,931 shares were purchased at a weighted average price of $13.22, with individual prices ranging from $13.04 to $13.30.
• Following these transactions, the total number of shares indirectly beneficially owned by Mr. Savitz through the trust is 39,851.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the purchases are made indirectly through a trust, which somewhat tempers the positive signal.

Positives

• The Chief Medical Officer's increased investment could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company insider believes the company's stock is undervalued or that the company's prospects are strong.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal.

Key Dates